Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Soleno Therapeutics Inc

Healthcare US SLNO

NoneUSD
0.00(0%)

Last update at 2026-06-04T21:46:50.327679Z

Day Range

--
LowHigh

52 Week Range

3.6953.82
LowHigh

Fundamentals

  • Previous Close 53.01
  • Market Cap1508.00M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-36.71200M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.07

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -24.06700M -30.91000M -24.63900M -30.77400M -11.84100M
Minority interest - - - - -
Net income -20.31900M -29.56100M -15.37500M -35.91500M -13.33500M
Selling general administrative 9.84M 10.81M 8.76M 6.93M 6.56M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 1.96M 1.96M 1.95M 1.96M 1.96M
Ebit -24.39700M -31.52800M -36.28900M -23.48600M -17.64600M
Ebitda -25.85100M -31.53500M -39.24600M -15.94400M -15.68300M
Depreciation and amortization -1.45400M -0.00700M -2.95700M 7.54M 1.96M
Non operating income net other - - 11.65M -7.28800M 2.46M
Operating income -24.39700M -31.52800M -36.28900M -23.48600M -14.30100M
Other operating expenses 25.11M 32.26M 31.95M 23.20M 13.73M
Interest expense -0.33000M 0.62M 0.00000M 0.00000M 0.06M
Tax provision - - - - 0.00000M
Interest income 0.30M 0.11M - 0.48M -
Net interest income 0.30M 0.11M 0.01M 0.15M -0.06200M
Extraordinary items - - - - -1.49400M
Non recurring - - - - -
Other items - - - - -
Income tax expense -3.74800M -1.34900M -9.26400M 5.14M 2.52M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 25.11M 32.26M 31.95M 23.20M 13.73M
Cost of revenue - - - - 0.00000M
Total other income expense net 0.33M 0.62M 11.65M -7.28800M 1.96M
Discontinued operations - - - - -1.49400M
Net income from continuing ops -24.06700M -30.91000M -24.63900M -30.77400M -11.84100M
Net income applicable to common shares -24.06700M -30.91000M -24.63900M -30.77400M -13.33500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 180.69M 26.50M 35.55M 64.98M 38.17M
Intangible assets 8.75M 10.69M 12.64M 14.58M 16.52M
Earning assets - - - - -
Other current assets 1.68M 1.04M 1.12M 1.02M 0.41M
Total liab 23.18M 16.15M 17.76M 19.43M 23.23M
Total stockholder equity 157.51M 10.35M 17.79M 45.55M 14.95M
Deferred long term liab - - - 0.54M 12.18M
Other current liab 8.08M 5.38M 0.32M 0.20M 0.38M
Common stock 0.03M 0.00800M 0.08M 0.08M 0.04M
Capital stock 0.03M 0.00800M 0.08M 0.08M 0.04M
Retained earnings -276.41000M -237.42200M -213.35500M -182.44500M -157.80600M
Other liab - 8.84M 9.58M 10.82M 18.11M
Good will - - - - -
Other assets 0.00000M - 0.04M 0.14M 0.06M
Cash 169.68M 14.60M 21.30M 49.22M 20.73M
Cash and equivalents - - - - -
Total current liabilities 11.51M 7.31M 8.01M 8.62M 4.96M
Current deferred revenue - - 4.15M 4.79M 2.28M
Net debt -169.27800M -14.44700M -20.84700M -49.08500M -20.42800M
Short term debt 0.27M 0.15M 0.28M 0.14M 0.30M
Short long term debt - - - - -
Short long term debt total 0.40M 0.15M 0.46M 0.14M 0.30M
Other stockholder equity 433.88M 247.76M 231.07M 227.91M 172.71M
Property plant equipment - 0.16M 0.45M 0.02M 0.02M
Total current assets 171.36M 15.65M 22.42M 50.24M 21.14M
Long term investments - - - - -
Net tangible assets - -0.34500M 5.16M 30.97M -1.57800M
Short term investments - - - - 0.00000M
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 3.15M 1.78M 3.25M 3.49M 2.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - - - -0.03100M
Additional paid in capital - - - - -
Common stock total equity - - - 0.08M 0.04M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -182.44500M -157.80600M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.16M - 0.04M 0.14M 0.06M
Deferred long term asset charges - - - - -
Non current assets total 9.33M 10.85M 13.13M 14.74M 17.03M
Capital lease obligations 0.40M 0.15M 0.46M 0.14M 0.30M
Long term debt total - - - - 0.00800M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.01300M -0.02200M -0.00700M 0.53M -0.18000M
Change to liabilities -1.47700M -0.23500M 2.04M 1.11M 0.21M
Total cashflows from investing activities -0.01300M -0.02200M -0.00700M 0.53M -0.18000M
Net borrowings - -0.00800M -0.01700M -0.00200M -0.00200M
Total cash from financing activities 14.09M -0.12800M 53.72M 14.48M 17.83M
Change to operating activities 0.72M -0.91300M 1.48M 1.44M -0.16700M
Net income -24.06700M -30.91000M -24.63900M -30.77400M -11.84100M
Change in cash -6.70200M -27.92000M 28.49M -2.36600M 5.96M
Begin period cash flow 21.30M 49.22M 20.73M 23.10M 17.14M
End period cash flow 14.60M 21.30M 49.22M 20.73M 23.10M
Total cash from operating activities -20.78100M -27.77000M -25.22400M -17.37500M -11.68300M
Issuance of capital stock 15.15M 0.00000M 53.72M 14.48M 16.50M
Depreciation 1.96M 1.96M 1.95M 1.96M 1.96M
Other cashflows from investing activities - - - 0.55M -0.17200M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - 0.02M 14.48M 16.50M
Other cashflows from financing activities -1.06000M -0.12000M 0.02M 0.53M 1.33M
Change to netincome 2.08M 2.33M -10.13700M 8.27M -2.45400M
Capital expenditures 0.01M 0.02M 0.00700M 0.02M 0.00800M
Change receivables - - - 0.06M -0.06400M
Cash flows other operating - - 5.56M -28.77000M -11.33400M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 28.49M -2.36600M 5.96M
Change in working capital -0.75600M -1.14800M 2.98M 2.50M 0.08M
Stock based compensation 2.53M 3.28M 1.50M 0.82M 0.99M
Other non cash items -0.45200M -0.44300M 4.62M 1.15M 1.00M
Free cash flow -20.79400M -27.79200M -25.23100M -17.39600M -11.69100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
SLNO
Soleno Therapeutics Inc		 - -% - - - - 7.65 -28.2104
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Soleno Therapeutics Inc

203 Redwood Shores Parkway, Redwood City, CA, United States, 94065

Key Executives

Name Title Year Born
Dr. Anish Bhatnagar M.D. Pres, CEO, COO & Director 1970
Mr. James H. MacKaness Chief Financial Officer 1964
Ms. Kristen Yen M.S. VP of Clinical Operations 1969
Ms. Patricia C. Hirano VP of Regulatory Affairs 1966
Mr. Anthony Wondka Sr. VP & GM 1962
Dr. Neil M. Cowen M.B.A., Ph.D., MBA Sr. VP of Drug Devel. NA
Dr. Anish Bhatnagar M.D. President, CEO, COO & Director 1970
Ms. Patricia C. Hirano Vice President of Regulatory Affairs 1966
Dr. Neil M. Cowen M.B.A., Ph.D. Senior Vice President of Drug Development NA
Ms. Meredith Manning M.B.A. Chief Commercial Officer 1973

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.